



Contact:

Dilek Mir
Director, Business Development &
Investor Relations
dmir@radiant-pharma.com
(Tel:) 714.881.0244

Radiant Pharmaceuticals Files International Patents In Australia and New Zealand

TUSTIN, CA—September 14, 2011 –Radiant Pharmaceuticals Corporation “the Company” or “Radiant” (OTCQX:RXPC) (OTCPK:RXPC), a developer and marketer of *In Vitro Diagnostic* (IVD) cancer tests, today announced it has filed for patent protection for its proprietary Onko-Sure® cancer test in Australia and New Zealand.

“Building an intellectual property position in foreign markets protects and supports sales of our proprietary Onko-Sure® cancer test globally. Both Australia and New Zealand have highly developed healthcare markets where we believe Onko-Sure® can add value as a minimally invasive, relatively low cost cancer diagnostic,” stated Radiant Chairman and CEO Douglas MacLellan.

The Onko-Sure® test kit is a 96-well ELISA test kit sold to clinical reference labs. Labs run individual tests prescribed by doctors. Blood samples can be run, in duplicate, for 40 people, on each test kit. Onko-Sure® is a non-invasive cancer blood test that has been shown, in a large body of published clinical research, to be effective in the detection of 19 different cancers.

For additional information on Radiant Pharmaceuticals Corporation and its products visit: www.radiant-pharma.com or e-mail info@radiant-pharma.com. For Investor Relations contact Dilek Mir at: ir@radiant-pharma.com or 714-881-0244.

The following table is intended to provide the latest information on Radiant’s business metrics:

RPC’s Business Metrics
Cash on hand: \$580,000*
*Approximate amount as of September 12, 2011
Shares Outstanding: 435 million*
*Approximate number as of September 12, 2011. 750 million shares authorized.
Outstanding Warrants & Options: 111 million*
*Approximate number as of September 12, 2011



About Radiant Pharmaceuticals:

Headquartered in Tustin, California, Radiant Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radiant-pharma.com.

Forward-Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radiant Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

###